홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

D-카르니틴

D-Carnitine

HCID 2724480
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
541-14-0
표준 SMILES
C[N+](C)(C)C[C@@H](O)CC(=O)[O-]
InChIKey
PHIQHXFUZVPYII-LURJTMIESA-N
분자식
C7H15NO3
평균 분자량
161.2 g/mol
단동위원소 질량
161.10519334

개요

(S)-carnitine is the (S)-enantiomer of carnitine. It is a conjugate base of a (S)-carnitinium. It is an enantiomer of a (R)-carnitine.

이름 및 식별자

우선 이름
D-Carnitine
IUPAC
(3S)-3-hydroxy-4-(trimethylazaniumyl)butanoate
현지명
D-카르니틴
영어명
D(+)-Carnitine
분자식
C7H15NO3
분자량
161.2

이름 및 동의어

D-carnitine541-14-0D-(+)-carnitine(+)-Carnitine(S)-carnitine(3S)-3-hydroxy-4-(trimethylazaniumyl)butanoateCarnitine, (+)-UNII-U9VY0ZOK7AU9VY0ZOK7ACARNITINE, D-(3S)-3-hydroxy-4-(trimethylammonio)butanoate(+)-D-CARNITINE
이름 더 보기
D-카르니틴D(+)-카르니틴D-Vitamin BTD-CARNITINEHCLCarnitine D-formD(+)-Carnitine,98%L-carnitine Impurity 1D(+)-Carnitine USP/EP/BPD-CARNITINE HYDROCHLORIDEDL-CARNITINE BENZYL ESTER CHLORIDE
CHEBI:11060S-(+)-3-hydroxy-4-trimethylaminobutyrate1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (S)-1-PROPANAMINIUM, 3-CARBOXY-2-HYDROXY-N,N,N-TRIMETHYL-, INNER SALT, (2S)-RefChem:130511L-I3-Trimethyl-I2-hydroxybutyrobetaine1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (S)-(9CI)625-884-0

데이터베이스 식별자

CAS
541-14-0
PubChem CID
2724480
ChEMBL
CHEMBL503189
ChEBI
CHEBI:11060
UNII
U9VY0ZOK7A
EC Number
625-884-0
Nikkaji
J94.155G

물성

구조 계산 물성

XLogP
-0.2
극성 표면적
60.4 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
3
무거운 원자 수
11
형식 전하
0
복잡도
134

물리화학적 성질

녹는점
197 °C · 197 °C
끓는 점
287.5 °C · 287.5°C (rough estimate)
밀도
1.1587 · 1.1587 (rough estimate)
굴절률
1.45 · 1.4500 (estimate)
저장 조건
2 · Inert atmosphere,2-8°C
용해도
메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태
고체
색상
흰색에서 황백색까지
Merck
13 · 13,1862
안정성
흡습성
InChI
InChI=1/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/s3
InChIKey
PHIQHXFUZVPYII-ISZMHOAENA-N
SMILES
C([C@@H](O)CC(=O)[O-])[N+](C)(C)C |&1:1,r|

화학적 성질

white to light yellow crystal powde

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

독성 정보

Exposure RoutesIntravenous, Oral. Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours.
Toxicity Summary · 1건

Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases.

Signs and SymptomsAdverse effects include hypertension, fever, tachycardia and seizures.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD<sub>50</sub> > 8g/kg (mouse, oral).

안전 데이터

wgk
3
rtecs
BP2979850
HS 번호
29391900
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36-37/39
위험 등급
IRRITANT

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

After oral administration L-carnitine which is unabsorbed is metabolized in the gastrointestinal tract by bacterial microflora. Major metabolites include trimethylamine N-oxide and [3H]-gamma-butyrobetaine. Route of Elimination: Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval. Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days. Half Life: 17.4 hours (elimination) following a single intravenous dose.

용도 및 제조

Uses · 1건

For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.

응용 분야 · 1건

용도Essential cofactor of fatty acid metabolism; required for the transport of fatty acids through the inner mitochondrial membrane. Synthetized primarily in the liver and kidney; highest concentrations found in heart and skeletal muscle. Dietary sources include red meat, dairy products, beans, avocado.

상·하류 제품 정보

하류 제품

L-카르니틴

추가 설명

정의ChEBI: The (S)-enantiomer of carnitine.

관련 반응

5건
반응 기록 만들기
HRID 64789 반응식
HRID 64789생성물로
HRID 64791 반응식
HRID 64791생성물로
HRID 64793 반응식
HRID 64793생성물로
HRID 1266631 반응식
HRID 1266631반응물로
HRID 1937765 반응식
HRID 1937765반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트